Suggested remit: To evaluate the benefits and costs of olipudase alfa within its marketing authorisation for treating Niemann-Pick disease types A and B for national commissioning by NHS England.
Status Awaiting development
Decision None selected
Process STA 2018
ID number 3913

Project Team

Project lead

Email enquiries


Key events during the development of the guidance:

Date Update
17 March 2022 (10:00) Scoping workshop
19 January 2022 - 16 February 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual